Optimal management of fungal infections of the skin, hair, and nails

American Journal of Clinical Dermatology

Volumn 5, Issue 4, 2004, Pages 225-237

  Gupta, Aditya K ^a,b,c   Cooper, Elizabeth A ^b   Ryder, Jennifer E ^b   Nicol, Karyn A ^b   Chow, Melody ^b   Chaudhry, Maria M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMOROLFINE; ANTIFUNGAL AGENT; BUTENAFINE; CHLORHEXIDINE; CICLOPIROX; CLOTRIMAZOLE; CORTICOSTEROID; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; OXICONAZOLE; POVIDONE IODINE; PYRITHIONE; SELENIUM SULFIDE; SULCONAZOLE; TERBINAFINE; TIABENDAZOLE; TOLNAFTATE;

CANDIDA; CLINICAL TRIAL; COMB; CONIDIUM; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HAIR LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; FAMILY HISTORY; FOOD AND DRUG ADMINISTRATION; FUNGUS; FUNGUS TRANSMISSION; GASTROINTESTINAL DISEASE; HAIR; HORTAEA WERNECKII; HUMAN; MALASSEZIA; MICROSPORE; MYCOSIS; NAIL INFECTION; ONYCHOMYCOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA NIGRA; TINEA PEDIS; TINEA VERSICOLOR; TRAVEL; TREATMENT OUTCOME; TRICHOPHYTON;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 4344582204     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405040-00003     Document Type: Review

References (155)

1. Wilmington M, Aly R, Frieden IJ. Trichophyton tonsurans tinea capitis in the San Francisco Bay area: increased infection demonstrated in a 20-year survey of fungal infections from 1974 to 1994. J Med Vet Mycol 1996; 34 (4): 285-7
2. Gupta AK, Summerbell RC. Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Med Mycol 1998; 36 (2): 55-60
3. Friedlander SF. The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Pediatr Infect Dis J 1999; 18 (2): 205-10
4. Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144: 321-7
5. López-Gómez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33 (10): 743-7
6. Cáceres-Ríos H, Rueda M, Ballona R, et al. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol 2000; 42: 80-4
7. Hussain I, Muzaffar F, Rashid T, et al. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs griseofulvin alone. Med Mycol 1999; 37: 97-9
8. Gupta AK, Adam P, Dlova N, et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 2001; 18 (5): 433-8
9. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002; 146 (5): 816-23
10. Jahangir M, Hussain I, Ul Hasan M, et al. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139: 672-4
11. Solomon BA, Collins R, Sharma R, et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997; 37 (2 Pt 1): 274-5
12. Filho ST, Cucé LC, Foss NT, et al. Efficacy, safety and tolerability of terbinafine for tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1, 2 and 4 weeks. J Eur Acad Dermatol Venereol 1998; 11: 141-6
13. Hamm H, Schwinn A, Bräutigam M, et al. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatol 1999; 140: 480-2
14. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996; 135: 86-8
15. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 1997; 37 (2 Pt 1): 272-3
16. Friedlander SF, Aly R, Krafchik B, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics 2002; 109 (4): 602-7
17. Yeates R, Laufen H, Zimmerman T, et al. Accumulation of fluconazole in scalp hair. J Clin Pharmacol 1998; 38: 138-43
18. Tanuma H, Doi M, Yaguchi A, et al. Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type: stratum corneum levels. Mycoses 1998; 41: 153-62
19. Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin 2003; 21 (3): 521-35
20. Gupta AK, Cooper EA, Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin 2003; 21 (3): 537-42
21. th ed. Montvale (NH): Thomson PDR, 2003: 1797-802
22. Gupta AK, Hofstader SL, Summerbell RC, et al. Treatment of tinea capitis with itraconazole capsule pulse therapy. J Am Acad Dermatol 1998; 39 (2 Pt 1): 216-9
23. Gupta AK, Adam P, De Doncker P. Itraconazole pulse therapy for tinea capitis: a novel treatment schedule. Pediatr Dermatol 1998; 15 (3): 225-8
24. Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol 1997; 137 (2): 251-4
25. Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol 1998; 139 (1): 104-6
26. Gupta AK, Adam P, Soloman R, et al. Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. Cutis 1999; 64 (3): 192-4
27. Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin 2003; 21 (3): 511-20
28. Burkhart CG. Coffee grinders assist pediatric dosing [letter]. Cutis 2000; 65 (5): 276
29. Friedlander SF, Skerlev M, Lipozencic J, et al. Relationship between terbinafine dose and complete cure rate in tinea capitis: analysis of phase II randomized trials [abstract]. J Eur Acad Derm Venereol 2001; 15 Suppl. 2: 221
30. Romero G, Garrido JA, Cortina P, et al. Efficacy of oral terbinafine in children with tinea capitis caused by Microsporum canis [abstract]. J Eur Acad Derm Venereol 2001; 15: 221
31. Koumantaki E, Kakourou T, Rallis E, et al. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol 2001; 18 (4): 339-42
32. Williams JV, Honig PJ, McGinley KJ, et al. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995; 96 (2 Pt 1): 265-7
33. Pomeranz AJ, Sabnis SS, McGrath GJ, et al. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med 1999; 153 (5): 483-6
34. Frieden IJ. Tinea capitis: asymptomatic carriage of infection. Pediatr Infect Dis J 1999; 18 (2): 186-90
35. Suarez S, Friedlander SF. Antifungal therapy in children: an update. Pediatr Ann 1998; 27 (3): 177-84
36. Gupta AK, Summerbell RC. Tinea capitis. Med Mycol 2000; 38 (4): 255-87
37. Neil G, Hanslo D, Buccimazza S, et al. Control of the carrier state of scalp dermatophytes. Pediatr Infect Dis J 1990; 9 (1): 57-8
38. Greer DL. Treatment of symptom-free carriers in management of tinea capitis. Lancet 1996; 348 (9024): 350
39. Hebert AA. Tinea capitis: current concepts. Arch Dermatol 1988; 124 (10): 1554-7
40. Higgins EM, Fuller LC, Smith CH. Guidelines for the management of tinea capitis: British Association of Dermatologists. Br J Dermatol 2000; 143 (1): 53-8
41. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/ Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34 (2 Pt 1): 290-4
42. Honig PJ. Tinea capitis: recommendations for school attendance. Pediatr Infect Dis J 1999; 18 (2): 211-4
43. Crespo Erchiga V, Delgado Florencio V. Malassezia species in skin diseases. Curr Opin Infect Dis 2002; 15: 133-42
44. Guého E, Midgley G, Guillot J. The genus Malassezia with description of four new species. Antonie van Leeuwenhoek 1996; 69: 337-55
45. Sugita T, Takashima M, Shinoda T, et al. New yeast species, Malassezia dermatis, isolated from patients with atopic dermatitis. J Clin Microbiol 2002; 40: 1363-7
46. Nell A, James SA, Bond CJ, et al. Identification and distribution of a novel Malassezia species yeast on normal equine skin. Vet Rec 2002; 150: 395-8
47. Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin 2003; 21 (3): 413-29
48. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin 2003; 21 (3): 401-12
49. El Euch D, Riahi I, Mokni M, et al. Ketoconazole forming gel in tinea versicolor (about 60 cases) [in French]. Tunis Med 1999; 77: 38-40
50. Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 1998; 39: 944-50
51. Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13: 73-6
52. Shemer A, Nathansohn N, Kaplan B, et al. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 1999; 10: 19-23
53. Fernandez-Nava HD, Laya-Cuadra B, Tianco EAV. Comparison of single dose 400mg versus 10-day 200mg daily dose ketoconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 64-6
54. Zaias N. Pityriasis versicolor with ketoconazole. J Am Acad Dermatol 1989; 20: 703-5
55. Hay RJ, Midgeley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9: 571-3
56. Savin RC. Systemic ketoconazole in tinea versicolor: a double-blind evaluation and 1-year follow-up. J Am Acad Dermatol 1984; 10: 824-30
57. Urcuyo FG, Zaias N. The successful treatment of pityriasis versicolor by systemic ketoconazole. J Am Acad Dermatol 1982; 6: 24-5
58. Faergemann J, Djarv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis 1982; 30: 542-50
59. Köse O, Bülent Tastan H, Riza Gür A, et al. Comparison of a single 400mg dose versus a 7-day 200mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13: 77-9
60. Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol 1996; 34: 785-7
61. Montero-Gei F, Robles ME, Suchil P. Fluconazole vs itraconazole in the treatment of tinea versicolor. Int J Dermatol 1999; 38: 601-3
62. Massone L, Pestarino A, Borghi S, et al. Oral itraconazole in the treatment of pityriasis versicolor: a comparison of two different dosage regimens. Micologia Dermatologica 1991; 5: 90-2
63. Del Palacio Hernanz A, Delgado Vicente S, Menendez Ramos F, et al. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9: S121-7
64. Estrada RA. Itraconazole in pityriasis versicolor. Rev Infect Dis 1987; 9: S128-30
65. Galimberti RL, Villalba I, Galarza S, et al. Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment. Rev Infect Dis 1987; 9: S134-8
66. Morales-Doria M. Pityriasis versicolor: efficacy of two five-day regimens of itraconazole. Rev Infect Dis 1987; 9: S131-3
67. Del Palacio-Hernanz A, Frias-Iniesta J, Gonzalez-Valle O, et al. Itraconazole therapy in pityriasis versicolor. Br J Dermatol 1986; 115: 217-25
68. Simoni S, Cilli P. Itraconazole in the treatment of pityriasis versicolor: results obtained in 30 patients. G Ital Dermatol Venereol 1991; 126: 41-3
69. Cuce LC, Belda W, Barbosa de Oliveira Ribeiro E. Itraconazole in the treatment of pityriasis versicolor: comparison between 5 and 7 days of treatment. Rev Inst Med Trop Sao Paulo 1990; 32: 181-4
70. Panconesi E, Difonzo E. Treatment of dermatophytoses and pityriasis versicolor with itraconazole. Rev Infect Dis 1987; 9: S109-13
71. Faergemann J. Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study. Mycoses 1988; 31: 377-9
72. Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol (Stockh) 1992; 72: 74-5
73. Shahid J, Ihsan Z, Khan S. Oral fluconazole in the treatment of pityriasis versicolor. J Dermatolog Treat 2000; 11: 101-3
74. Amer MA, Abdallah MA, Abdel-Aal MA, et al. Fluconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 938-46
75. Cullen SI, Frost P, Jacobson C, et al. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7: 574-83
76. Savin R, Eisen D, Fradin MS, et al. Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol 1999; 38: 863-5
77. Vermeer BJ, Staats CCG. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997; 194: 22-4
78. Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil dermgel. Dermatology 1997; 197: 19-21
79. Aste N, Pau M, Pinna AL, et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353-7
80. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13: 51-60
81. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-12
82. Pierard-Franchimont C, Pierard GE, Arrese JE, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202: 171-6
83. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116: 213-6
84. Pierard GE, Pierard-Franchimont C, Van Cutsem J, et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991; 30: 806-9
85. Stratigos J, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Am Acad Dermatol 1988; 19: 850-3
86. Skinnèr RB, Noah PW, Taylor RM, et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12: 852-6
87. Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-7
88. Caputo R, Barbareschi M. Itraconazole: new horizons. G Ital Dermatol Venereol 2002; 137: 1-7
89. Dupuy P, Maurette C, Amoric JC, et al. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-7
90. Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: a multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144: 854-7
91. Faergemann J, Fredriksson T. Tinea versicolor: some new aspects on etiology, pathogenesis, and treatment. Int J Dermatol 1982; 21: 8-11
92. Gupta AK, Kohli Y, Li A, et al. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole, and terbinafine. Br J Dermatol 2000; 142: 758-65
93. Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002; 138: 69-73
94. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin 2003; 21 (3): 431-62
95. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol 1996; 34: 282-6
96. Physicians' desk reference. 57th ed. Montvale (NJ): Thomson PDR, 2003
97. Hay RJ, Moore M. Mycology. In: Champion RH, Burton JL, Burns DA, et al., editors. Textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998: 1290-312
98. Burke WA: Tinea nigra: treatment with topical ketoconazole. Cutis 1993; 52: 209-11
99. Gip L. Black piedra: the first case treated with terbinafine (Lamisil®). Br J Dermatol 1994; 130 Suppl. 43: 26-8
100. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Piedra. J Am Acad Dermatol 1996; 34: 122-4
101. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993; 28: S2-7
102. Gupta AK, Chow M, Daniel CR, et al. Treatments of tinea pedis. Dermatol Clin 2003; 21 (3): 431-62
103. Leyden JJ, Aly R. Tinea pedis. Semin Dermatol 1993; 12: 280-4
104. Brooks KE, Bender JF. Tinea pedis: diagnosis and treatment. Clin Podiatr Med Surg 1996; 13: 31-46
105. Masri-Fridling GD. Dermatophytosis of the feet. Dermatol Clin 1996; 14: 33-40
106. Gupta AK. Onychomycosis in the elderly. Drugs Aging 2000; 16 (6): 397-407
107. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicenter study. Br J Dermatol 1997; 136: 786-9
108. Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000; 39 (10): 746-53
109. Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000; 14 (6): 466-9
110. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43: 244-8
111. De Cuyper C, Hindryckx PHFB. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141 Suppl. 56: 15-20
112. Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126 Suppl. 39: 33-5
113. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl. 39: 36-9
114. De Backer M, De Keyser P, Massart DL, et al. Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16-week oral treatment of toenail onychomycosis: a double-blind multicentre trial. In: Hay RJ, editor. International perspective on Lamisil. London: CCT Healthcare Communications, 1994: 39-43
115. Brautigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ 1995; 311: 919-22
116. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3
117. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-5
118. Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis: a double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol 1997; 77: 66-9
119. Tausch I, Brautigam M, Weidinger G, et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy: the Lagos V Study Group. Br J Dermatol 1997; 136: 737-42
120. De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998; 38: S57-63
121. Billstein S, Kianifard F, Justice A. Terbinafine vs placebo for onychomycosis in black patients. Int J Dermatol 1999; 38: 377-9
122. Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999; 79: 221-3
123. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis: the LION Study Group. BMJ 1999; 318: 1031-5
124. Kejda J. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999; Spec No: 12-5
125. Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142: 97-102
126. Warshaw EM, Carver SM, Zielke GR, et al. Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Arch Dermatol 2001; 137: 1253
127. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 2002; 146: 250-3
128. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-7
129. De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132: 34-41
130. Havu V, Brandt H, Heikkila H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-4
131. Chen J, Liao W, Wen H, et al. A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses 1999; 42: 93-6
132. Gupta AK, Maddin S, Arlette J, et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatolog Treat 2000; 11: 33-7
133. Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996; 35: 110-1
134. Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis. Cutis 1997; 59: 217-20
135. Haneke E, Tajerbashi M, De Doncker P, et al. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology 1998; 196: 323-9
136. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S77-86
137. Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin: LAGOS II Study Group. Arch Dermatol 1995; 131: 919-22
138. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001; 145 Suppl. 60: 15-9
139. Baran R, Feuilhade M, Datry A, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-83
140. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol 2001; 145 Suppl. 60: 21-6
141. Gupta AK. P400: Evaluation of the mycological cure rates when ciclopirox nail lacquer is used in combination with oral terbinafine to treat onychomycosis: six month interim results [abstract]. JAAD 2004; 50 (3): 104
142. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-8
143. Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 2000; 15: 112-5
144. Gupta AK, Scher RK, Rich P. Fluconazole for the treatment of onychomycosis: an update. Int J Dermatol 1998; 37: 815-20
145. English MP, Atkinson R. An improved method for the isolation of fungi in onychomycosis. Br J Dermatol 1973; 88: 237-41
146. Gupta AK, Cooper EA, MacDonald P, et al. Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi. J Clin Microbiol 2001; 39: 2115-21
147. Gupta AK, Gregurek-Novak T, Konnikov N, et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg 2001; 5: 206-10
148. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-8
149. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000; 42: 217-24
150. Baran R, Feuilhade M, Combernale P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-83
151. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 Suppl. 1: 41-3
152. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001; 145 Suppl. 60: 21-6
153. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000; 22: 33-52
154. Gupta AK, Horgan-Bell CB, Summerbell RC. Onychomycosis associated with Onychocola canadensis: ten case reports and a review of the literature. J Am Acad Dermatol 1998; 39: 410-7
155. Gupta AK, Daniel III CR. Onychomycosis: strategies to reduce failure and recurrence. Cutis 1998; 62: 189-91